• Immunovant director Atul Pande exercised stock options for 1,500 common shares at $8.43 on June 26, 2026.
• Pande sold 1,500 common shares at $38.01 on June 26, 2026.
• Directly held common shares ended at 116,731.
• Stock options outstanding ended at 68,181, reflecting a fully vested award.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunovant Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001764013-26-000071), on June 26, 2026, and is solely responsible for the information contained therein.